ALK inhibitors, including crizotinib, alectinib, ceritinib, brigatinib, and lorlatinib have been approved in Taiwan, but only crizotinib, alectinib, and ceritinib are reimbursed by the NHI as the first-line treatment for advanced ALK-positive NSCLC [1]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.